patent analysis in this report are remdesivir, ruxolitinib, favipiravir, molnupiravir and nirmatrelvir, and the … biotherapeutics tocilizumab, siltuximab and sarilumab. … support national patent offices and interested parties in developing countries with information that can serve as guidance for …

patent analysis in this report are remdesivir, ruxolitinib and favipiravir, and the biotherapeutics tocilizumab, siltuximab … support national patent offices and interested parties in developing countries with information that can serve as guidance for … the examination of the claims contained in relevant patents or patent applications. The medicines considered for the …

prevention of COVID-19. The aim of the report is to support national patent offices and interested parties in developing … countries with information that can serve as guidance for the examination of the claims contained in relevant patents or patent … applications. The antibody combination considered for the patent analysis in this paper are Casirivimab and Imdevimab. The vaccines …

Since COVID-19 was first identified, infections from the virus and the death toll have spiked abysmally. The pandemic … and psychological ramifications associated with the pandemic are also immense. The threat posed by COVID-19 on global … health and the economic downturn resulting thereof necessitates the development of health technologies (such as medicines and …

The COVID-19 pandemic has caused Governments to contemplate measures to override patents and other intellectual … devices. This paper discusses whether the COVID-19 pandemic may be considered an “emergency in international relations” and … overriding IPRs otherwise required to be made available or enforced. It concludes that the pandemic constitutes an emergency in …

prevention of COVID-19. The aim of the report is to support national patent offices and interested parties in developing … countries with information that can serve as guidance for the examination of the claims contained in relevant patents or patent … applications. The antibody combination considered for the patent analysis in this paper are Casirivimab and Imdevimab. The vaccines …